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PENGAWALATURAN PEMBEZAAN RESEPTOR AKTIVASI PEMBIAKAN 
PEROKSISOM GAMMA (PPARγ) OLEH SITOKINA DI DALAM SEL 
TURUNAN MAKROFAJ MURIN J774.2: PENGENALPASTIAN LALUAN 
ISYARAT TRANSDUKSI FAKTOR NEKROSIS TUMOR ALFA (TNFα) DI 
DALAM PENGAWALATURAN PENGEKSPRESAN GEN PPARγ 
 
ABSTRAK 
 
Aterosklerosis merupakan punca kematian utama di negara-negara 
maju. Peranan PPARγ dalam makrofaj yang diaktifkan oleh sitokina adalah 
penting di dalam patogenesis aterosklerosis. Namun, mekanisme molekul yang 
tepat yang mana sitokina mengawalatur pengekspresan gen PPARγ masih 
kurang difahami. Di dalam kajian ini, kami mengkaji kesan empat sitokina iaitu 
TNFα, IFNγ, IL-1α dan IL-1β ke atas pengekspresan mRNA, protein dan aktiviti 
pengikatan DNA PPARγ di dalam sel turunan makrofaj murin J774.2, model 
yang paling lazim digunakan untuk aterosklerosis. TNFα dan IFNγ didapati 
merencat pengekspresan mRNA dan protein PPARγ serta aktiviti pengikatan 
DNA. Sebaliknya, IL-1β merangsangkan peningkatan pengekspresan PPARγ 
pada peringkat mRNA, protein dan aktiviti pengikatan DNA. IL-1α pula tidak 
mempunyai kesan ke atas pengekspresan PPARγ dan aktiviti pengikatan DNA. 
Memandangkan perubahan dalam kandungan protein dan aktiviti pengikatan 
DNA di dalam makrofaj yang dirawat dengan sitokina selaras dengan 
perubahan dalam mRNA PPARγ, keputusan ini mencadangkan dengan kukuh 
bahawa pengekspresan PPARγ dan aktiviti pengikatan DNA dikawalatur pada 
peringkat metabolisme mRNA. Di antara empat sitokina yang digunakan, TNFα 
didapati paling berkesan di dalam merencat pengekspresan mRNA PPARγ. 
Ujian aktinomisin D menunjukkan bahawa paras ekspresi mRNA PPARγ 
dikawalatur pada peringkat kadar transkripsi gen, dan bukannya pada peringkat 
 xxi
kestabilan mRNA dalam sel J774.2 yang dirawat dengan TNFα. Penggunaan 
perencat-perencat spesifik terhadap laluan isyarat transduksi MAP kinas 
(PD98095, U0126, SB202190 dan SP600125) menunjukkan TNFα merencat 
paras mRNA PPARγ melalui laluan p42 ERK dan p46/54 JNK, yang kemudian 
mengaktifkan dan merangsang pengikatan c-Jun dan ATF2 ke elemen 
rangsangan cAMP (CRE) pada promoter mPPARγ1. Oleh itu, kajian ini 
menyediakan pandangan baru untuk laluan berpotensi yang mungkin terlibat di 
dalam pengawalaturan pengekspresan PPARγ oleh TNFα di dalam sel turunan 
makrofaj J774.2, dan mencadangkan satu sasaran berpotensi untuk halangan 
terapeutik terhadap aterosklerosis.      
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DIFFERENTIAL REGULATION OF PEROXISOME PROLIFERATOR 
ACTIVATED RECEPTOR GAMMA (PPARγ) BY CYTOKINES IN MURINE 
MACROPHAGE J774.2 CELL LINE: ELUCIDATION OF SIGNAL 
TRANSDUCTION PATHWAYS OF TUMOUR NECROSIS FACTOR ALPHA 
(TNFα) IN REGULATING MACROPHAGE PPARγ GENE EXPRESSION 
 
ABSTRACT 
 
Atherosclerosis is the leading cause of death in developed countries. The 
role of the PPARγ in cytokine-activated macrophages is of crucial importance in 
the pathogenesis of atherosclerosis. However, the precise molecular 
mechanisms by which cytokines regulate PPARγ gene expression are poorly 
understood. In the present study, we evaluated the effects of four cytokines i.e. 
TNFα, IFNγ, IL-1α and IL-1β on the expression of PPARγ mRNA, protein and 
DNA binding activity in the murine macrophage J774.2 cell line, the widely used 
model for atherosclerosis. It was demonstrated that TNFα and IFNγ inhibited the 
PPARγ mRNA and protein expressions as well as DNA binding activity. By 
contrast, IL-1β induced a marginal increase at the levels of PPARγ mRNA, 
protein content and DNA binding activity. IL-1α, however, had no significant 
effects on the PPARγ gene expression and DNA binding activity. Since the 
changes observed in the PPARγ protein content and DNA binding activity in 
cytokine-treated macrophages followed closely the corresponding changes in 
PPARγ mRNA expression, the results strongly suggest that the PPARγ 
expression and binding activity were mainly regulated at the levels of mRNA 
metabolism.  Amongst four cytokines used, TNFα was found to produce the 
most significant inhibition of PPARγ mRNA expression. Actinomycin D 
experiment showed that the level of PPARγ mRNA expression was mainly 
regulated at the level of rate of gene transcription and not at the level of mRNA 
 xxiii
stability in TNFα-treated J774.2 cells. The use of specific inhibitors against MAP 
kinase signal transduction pathways (PD98095, U0126, SB202190 and 
SP600125) demonstrated that TNFα inhibited the mRNA levels of PPARγ via 
p42 ERK and p46/54 JNKs pathways, which in turn, activated and induced the 
binding of c-Jun and ATF2 to cAMP-responsive elements (CRE) in mPPARγ1 
promoter. Thus, this study provides novel insights into the potential pathways 
that may be responsible for the molecular regulation of macrophage PPARγ 
gene expression by TNFα in macrophage J774.2 cell line, and suggests a 
potential target for therapeutic intervention against atherosclerosis. 
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CHAPTER 1  
INTRODUCTION 
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1.1 Background 
Atherosclerosis is the leading cause of death in the United States and 
the cause of more than half of all mortality in the developed countries. It is a 
long-term chronic disease characterized by the accumulation of lipids and 
fibrous connective tissue in the large arteries, accompanied by a local 
inflammatory response (Lusis, 2000). As the cholesterol plaque, or lesions, 
build up in the arteries over time, the risk for disease increases. 
Atherosclerotic coronary heart disease is the underlying cause for most heart 
attacks, and one of the most common causes for congestive heart failure, 
cardiac arrhythmias and sudden death (Lusis, 2000). 
Epidemiological studies have revealed several genetic and 
environmental risk factors predisposing to atherosclerosis. Smoking, 
metabolic disorders clustering with insulin resistance, such as dyslipidemia, 
hypertension, diabetes, high cholesterol, and family history of heart disease, 
are particularly important risk factors. Predisposing symptoms of the disease 
include high blood pressure and elevated cholesterol, especially elevated 
LDL-cholesterol.  
Research conducted during the past decade has led to an 
understanding of a relationship between the role of nuclear receptor 
peroxisome proliferator activated receptor γ (PPARγ) in macrophage and the 
biological basis for arthrosclerosis (Tontonoz et al., 1998; Marx, 1998b; 
Chinetti, 1998; Ricote, 1999). For instance, PPARγ, upon activation, has been 
demonstrated to promote monocyte differentiation to macrophage and 
increase the uptake of oxidized LDL by macrophages to be transformed into 
foam cells (Tontonoz et al., 1998). It has also been shown to be highly 
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expressed in macrophage-derived foam cells and atherosclerotic plaque 
(Marx, 1998b). By contrast, PPARγ has also been demonstrated to have an 
anti-atherogenic effect. For example, it was reported that PPARγ is a potent 
negative regulator in the development of atherosclerosis (Ricote, 1999) and 
has the ability to induce apoptosis of human monocyte-derived macrophages 
(Chinetti, 1998).  
 
1.2 Peroxisome proliferators activated receptors (PPARs) 
Peroxisome proliferators activated receptors (PPARs) are a family of 
transcription factors that belong to the superfamily of nuclear receptors. The 
PPAR family consists of three distinct subtypes, termed α (NR1C1), β/δ 
(NR1C2) and γ (NR1C3), all of which display tissue-specific expression 
patterns reflecting their biological functions (Pineda-Torra et al., 2001).  
All three PPAR isoforms possess similar structural and functional 
features. Principally, four functional domains have been identified, called A/B, 
C, D and E/F (Figure 1.1). The N-terminal A/B domain contains a ligand-
independent activation function 1 (AF-1) (Werman et al., 1997) responsible for 
the phosphorylation of PPAR. The DNA binding domain (DBD) or C domain 
promotes the binding of PPAR to the peroxisome proliferator response 
element (PPRE) in the promoter region of target genes (Kliewer et al., 1992). 
The D site is a docking domain for cofactors. The E/F domain or ligand-
binding domain (LBD) is responsible for ligand specificity and activation of 
PPAR binding to the PPRE, which increases the expression of targeted 
genes.  
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Figure 1.1 Schematic representation of the structural domains of PPAR. 
PPAR consists of four distinct functional domains. The A/B domain locates at 
the N-terminal with AF-1 is responsible for phosphorylation, the domain C is 
implicated in DNA binding, domain D is the docking region for cofactors and 
domain E/F is the ligand binding domain, containing AF-2, which promotes the 
recruitment of cofactors required for gene transcription.  
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 Recruitment of PPAR co-factors to assist the gene transcription 
processes is carried out by the ligand-dependent activation function 2 (AF-2), 
which is located in the E/F domain (Berger & Moller, 2002). 
Like other members of the nuclear receptor gene family, the PPAR 
subtypes possess a common domain structure which contains DNA-binding 
domains (DBD) and ligand-binding domains (LBD). Amino acid sequence 
comparison of DBD amongst PPAR subtypes shows they are highly 
conserved indicating that they share similar DNA binding site presence on the 
promoter region of the target genes, while the LBD have a slightly lower level 
of conservation across the subtypes (Figure 1.2) suggesting that they are 
ligand-specific. The NH2-terminal domain of the subtypes shows low 
sequence identity which is responsible for differences in the biological function 
of the subtypes (Castillo et al., 1999). 
 
1.3 Peroxisome proliferator-activated receptor γ (PPARγ) 
PPARγ was first identified as a component of an adipocyte 
differentiation-dependent regulatory factor (ARF6) that binds to the well-
characterized, fat cell-specific enhancer of the adipocyte fatty acid-binding 
protein (aP2) gene (Tontonoz et al., 1994a; Tontonoz et al., 1994b).  
PPARγ, like the other PPARs, is an obligate heterodimer with another 
member of the nuclear receptor subfamily, the retinoic X receptors (RXR), the 
receptor for 9-cis-retinoic acid. Upon heterodimerization with RXR, PPARγ 
binds to peroxisome proliferator response element (PPRE) which in turn 
regulates downstream target genes (Figure 1.3) (Kliewer et al., 1992).  
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Figure 1.2 Comparison of amino acid identities of the DBD and LBD of 
human and mouse PPAR isoforms. Amino acid sequences are represented 
by open bars and numbers in the bars show the percentage of amino acid 
identity between human and mouse isoforms relative to PPARα. N, N-
terminus; DBD, DNA-binding domain; LBD, ligand-bindind domain and C, C-
terminus (Murphy & Holder, 2000). 
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Figure 1.3 Gene transcription mechanisms of PPARγ. PPAR/RXR 
heterodimer binds to a PPRE in the regulatory regions of target genes, 
thereby governing the expression of the downstream target genes. 
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Structurally, PPRE consists of direct repeat of the nuclear receptor 
hexameric DNA core recognition motif AGGTCA separated by one nucleotide, 
known as DR-1 response elements (Lemberger et al., 1996; Juge-Aubry et 
al., 1997). 
 
1.3.1 The structural organization of PPARγ gene 
PPARγ has been cloned from a number of species, including mouse 
(Zhu et al., 1993; Kliewer et al., 1994), hamster (Aperlo et al., 1995), cattle 
(Sundvold et al., 1997), pig (Houseknecht et al., 1998) and human (Greene et 
al., 1995; Elbrecht et al., 1996).  
The PPARγ gene, which has 9 exons (Figure 1.4) and extends over 
more than 100kb of genomic DNA for human (Fajas et al., 1997) and 105kb 
for mouse (Zhu et al., 1995), is mapped to chromosome 6 E3-F1 by in situ 
hybridization (Zhu et al., 1995). 
In contrast to human, in which four PPARγ mRNA isoforms have been 
identified so far, i.e., PPARγ1, γ2 (Fajas et al., 1997), γ3 (Fajas et al., 1998) 
and γ4 (Sunvold & Lien, 2001), in mouse, only two PPARγ mRNA isoforms 
have been detected, termed PPARγ1 and γ2 (Zhu et al., 1995). The two 
mRNA isoforms of PPARγ arise as products of different promoter usage and 
alternative splicing from a single PPARγ gene, which differ only at their 5’ 
ends (Figure 1.4). 
 
 
 
 
 
   
 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Structural organization of mPPARγ gene. The eight exons (A1, 
A2, and 1-6) encoding the mPPARγ1 and the seven exons (B and 1-6) 
encoding the mPPARγ2 are shown in the genomic DNA. γ1P and γ2P 
represent the promoter of mPPARγ1 and mPPARγ2, respectively.   
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 The PPARγ1 is encoded by 8 exons whereas PPARγ2 is encoded by 7 
exons (Figure 1.4). Consistent with the production of two PPARγ mRNAs, 
there are two PPARγ promoters, each with a specific and distinctive 
expression pattern (Zhu et al., 1995). The two PPARγ transcripts differ in their 
5’end. PPARγ1 mRNA codes for one protein, while PPARγ2 codes for a 
different protein containing 28 additional amino acids at the N-terminus to the 
start codon of PPARγ1 for human (Sundvold et al., 1997) and 30 additional 
amino acids for mouse (Zhu et al., 1995).  
 In PPARγ1, the two most upstream exons A1 and A2 comprise the 5’ 
untranslated region (UTR) and are spliced to the six most 3’ proximal exons 
(Kliewer et al., 1992) which encompass the common coding region shared by 
the two isoforms. The 5’ untranslated region (UTR) of PPARγ2 plus the 
additional 30 N-terminal amino acids specific to PPARγ2 are encoded by exon 
B, located between exon A2 and exon 1 (Zhu et al., 1995).  
Thus, exons A1 and A2 are spliced with exon 1 to 6 to give rise to 
PPARγ1 mRNA. PPARγ2 mRNA is generated by splicing of exon B to exon 1 
to 6. Each of the two zinc fingers of the DNA-binding domains of mPPARγ is 
encoded by a separate exon (exon 2 and 3, respectively). The ligand-binding 
domain is encoded by two exons which are exons 5 and 6.    
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1.3.2 Tissue distribution and expression patterns of PPARγ 
 PPARγ mRNA is expressed in a tissue-specific manner. A comparison 
of the tissue-distribution of PPARγ transcripts among different species shows 
PPARγ mRNAs are specifically expressed at high levels in mammalian 
adipose tissue, large intestine and hematopoietic cells (Tontonoz et al., 
1994b) and variable, but generally at lower levels in other tissues like kidney, 
liver and small intestine  (Aperlo et al., 1995). Interestingly, PPARγ is barely 
detectable in muscle (Fajas et al., 1997; Auboeuf et al., 1997).  
Analysis of the tissue distribution of the two PPARγ isoforms revealed 
that PPARγ1 shows rather ubiquitous distribution, whereas PPARγ2 had a 
more restricted distribution. PPARγ2 is much less abundant in all tissues 
analyzed compared to PPARγ1, the predominant PPARγ isoform. The only 
tissue expressing significant amounts of PPARγ2 is adipose tissue, where its 
mRNA makes up about 20% of total PPARγ mRNA (Fajas et al., 1997; 
Auboeuf et al., 1997).  
Previous research showed that the expression of PPARγ2 mRNA is 
markedly increased very early during adipocyte differentiation (Chawla et al., 
1994; Tontonoz et al., 1994b; Tontonoz et al., 1994c). Early induction of 
PPARγ2 expression during adipocyte differentiation and its adipose tissue 
selectivity suggesting its pivotal role in the regulation of adipocyte 
differentiation.  
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In addition to the role in adipocyte differentiation, PPARγ has also been 
shown to play a pivotal role in monocytes differentiation. It was reported that 
PPARγ is expressed in cells of the monocyte/macrophage lineage (Tontonoz 
et al., 1998; Greene et al., 1995; Ricote et al., 1998b; Jiang et al., 1998; 
Chinetti et al., 1998; Marx et al., 1998b) suggesting that PPARγ is involved in 
the development of monocyte along the macrophage lineage, in particular in 
the conversion of monocytes to foam cell in the development of 
atherosclerosis (Tontonoz et al., 1998).  
PPARγ is also found expressed in several carcinomas, suggesting a 
role in the differentiation of cancer cell lines and in cell cycle regulation 
(Tontonoz et al., 1997; Altiok et al., 1997; Kubota et al., 1998; Mueller et al., 
1998; DuBois et al., 1998). 
 
1.3.3 Natural and synthetic ligands of PPARγ 
 PPARγ is a ligand-activated transcription factor. The binding of ligands 
to the receptor greatly increases its transcriptional activity. The ligand binding 
domain (LBD) of PPARγ consist of 13 α helices and a small four-stranded β 
sheet forming a large Y-shaped hydrophobic pocket (Figure 1.5). This pocket 
represents the ligand binding cavity and has a volume of approximately 1300 
Å3, which is about twice that of the other nuclear receptors (Wagner et al., 
1995). 
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Figure 1.5 Three-dimensional structure of ligand binding domains of 
PPARγ. An X-ray crystal structure of PPARγ (yellow ribbon) is shown. PPARγ 
is shown associated to LXXLL peptides (blue ribbons), the signature motif of 
the receptor coactivators. The solvent-accessible ligand binding pocket is 
displayed as an off-white surface (from Xu et al., 2001). 
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The PPARγ ligands occupy ~30 –40% of the pocket, in contrast to the 
thyroid hormone receptor, where the ligand fills around 90% of the pocket 
(Wagner et al., 1995). Besides its large size, another characteristic feature of 
the PPARγ ligand binding pocket is that its bottom portion is sealed by helix 2’, 
which is absent in other nuclear receptors. This particular helix may increase 
the size of the pocket, and possibly participates in an entry channel for the 
ligand.  
The structural alignment of the ligand binding cavities of PPARγ 
showed that the ligand selectivity depends on the identity of a single amino 
acid histidine in helix 5. This selectivity seems to be conserved between 
different ligand classes and corresponds to an intrinsic property of the 
receptors (Xu et al., 2001). The characteristics of the PPARγ LBD give insight 
into the propensity of PPARγ to interact with a variety of natural and synthetic 
compounds (Xu et al., 1999; Nolte et al., 1998).  
 A broad spectrum of synthetic and naturally occurring substances can 
serve as PPARγ ligands, including pharmacological molecules, as well as fatty 
acids and fatty acid-derived products. PPARγ is bound and activated by 
naturally occurring arachidonic acid metabolites derived from cycloxygenase 
and lipoxygenase pathways, such as 15-deoxy-Δ12,14-prostaglandin J2 (15-
dPGJ2), 12-hydroxyeicosatetraenoic acid (12-HETE) and 15-hydroxyeicosa-
tetraenoic acid (15-HETE) (Forman et al., 1995; Kliewer et al., 1995; Nagy et 
al., 1998; Huang et al., 1999) (Figure 1.6). 
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Figure 1.6 Natural ligands of PPARγ. PPARγ is activated by natural 
activators derived from fatty acids through the cycloxygenase and 
lipoxygenase pathways such as 15-dPGJ2, 12-HETE, 15-HETE, 9-HODE and 
13-HODE. 
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In addition, other eicosanoids and unsaturated fatty acids are also 
reported to bind and activated PPARγ. This has been shown for the ω-3 
polyunsaturated fatty acids, α-linolenic acid, eicosapentaenoic acid and 
docohexanoic acid (Krey et al., 1997; Kliewer et al., 1997). It was also shown 
that two eicosanoids present in oxidized low density lipoproteins (oxLDL) i.e. 
9-hydroxyoctadecadienoic acid (9-HODE) and 13-hydroxyoctadecadienoic 
acid (13-HODE) are potent endogenous PPARγ ligands (Nagy et al., 1998) 
(Figures 1.6 and 1.7). 
The synthetic compounds, thiazolidinediones (TZDs) or “glitazones” 
which include troglitazone, pioglitazone and rosiglitazone (Figure 1.8) are the 
first compounds reported as high-affinity PPARγ agonists (Lehmann et al., 
1995). TZDs are currently being used for the treatment of insulin resistance 
and type II diabetes mellitus. TZD treatment results in a concomitant fall in 
glucose and insulin levels, through its insulin-enhancing action (Schwartz et 
al., 1998).  
Non-TZDs such as isoxazolidinedione JTT-501 (Shibata et al., 1999) 
and the tyrosine-based GW-7845 (Figure 1.8) have PPARγ activation 
properties with significant anti-diabetic and anti-carcinogenic activities in 
rodents (Cobb et al., 1998; Suh et al., 1999). 
Certain non-steroidal anti-inflammatory drugs (NSAIDs), including 
indomethacin and ibuprofen, had been shown to bind and activate PPARγ at 
high micromolar concentrations (Lehmann et al., 1997). Several other 
NSAIDs, including fenoprofen and flufenamic acid, were also shown to be 
weak PPARγ agonists (Lehmann et al., 1997). 
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Figure 1.7 Structure of natural ligands of PPARγ. 15-deoxy-Δ12,14-
prostaglandin J2 (15-dPGJ2), eicosapentaenoic acid (EPA), 9-hydroxy-
octadecadienoic acid (9-HODE) and 13-hydroxyoctadecadienoic acid (13-
HODE) are potent PPARγ ligands. 
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Figure 1.8 Structure of synthetic agonists and antagonists of PPARγ. 
Troglitazone, pioglitazone, rosiglitazone, JTT-501, GW-7845 and CDDO are 
agonists of PPARγ; BADGE and LG-100641 are antagonists of PPARγ.   
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Novel PPARγ partial agonists and antagonists have been recently 
identified. Triterpenoid 2-cyano-3, 12-dioxooleana-1,9-dien-28-oic acid 
(CDDO) (Figure 1.8) is a partial agonist with anti-inflammatory properties 
(Wang et al., 2000). Bisphenol diglycidyl ether (BADGE) and LG-100641 
(Figure 1.8) are recently identified PPARγ antagonists (Wright et al., 2000; 
Mukherjee et al., 2000). Although these compounds have less clinical 
significance, they may be useful in understanding PPARγ physiology and the 
identification of new ligands. 
In addition to synthetic chemical methods, research in natural products 
has also yielded potent PPARγ agonists from several medicinal plants. 
Saurufuran A from Saururus chinensis (Saururaceae) (Hwang et al., 2002), 
flavonoids such as chrysin, apigenin and kampferol (Liang et al., 2001) and 
phenolic compounds from Glycyrrhiza uralensis (Fabaceae) (Kuroda et al., 
2003) are recently identified PPARγ agonists. 
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1.3.4 Cofactors for the PPARγ 
Cofactors have been shown to play an important part in the 
transcriptional control of PPARγ. They act as coactivators or corepressors that 
mediate the ability of PPARγ to initiate or suppress the transcription process. 
They interact with nuclear receptors in a ligand-dependent manner 
(Lemberger et al., 1996). 
Initially, it was thought that the cofactors simply bridge PPARγ with the 
basic transcriptional machinery. However, it has become clear that these 
cofactors also carried several enzymatic activities, suggesting that they could 
control gene expression by specifically modifying chromatin and DNA 
structure (Glass et al., 1997; Pazin & Kadonaga, 1997; Moras & Gronemeyer, 
1998). It is suggested that in the absence of any ligand, PPARγ may bind to 
corepressors which extinguish its transcriptional activity by the recruitment of 
histone deacetylases. Histone hypoacetylation is associated with condensed 
nucleosomes and thereby transcriptionally silent (Glass et al., 1997; Pazin & 
Kadonaga, 1997; Moras & Gronemeyer, 1998).  
Ligand binding induces a conformational change in the receptor that 
results in the dissociation of corepressors and removal of histone 
deacetylases from DNA with subsequent recruitment of coactivator complexes 
that contain proteins with histone acetyltransferase activity. Acetylation is 
associated with changes of nucleosome conformation which modulates 
accessibility of promoter regions and facilitates transcription, thereby 
increases the transcription of target gene (Glass et al., 1997; Pazin & 
Kadonaga, 1997; Moras & Gronemeyer, 1998) (Figure 1.9).  
 
 21
 
 
 
 
 
 
 
   Inactive state       Active state 
 
Figure 1.9 Transcriptional activation of nuclear receptors. Transcriptional 
activation of nuclear receptors requires, in general, the release of corepressor 
(CoR) complexes, which contain histone deacetylase activity (HDAC), and the 
recruitment of coactivators (CoA), which target histone acetyl transferases 
(HAT) to the promoter. The differential docking of cofactors is facilitated by 
structural changes brought about by ligand-binding or receptor 
phosphorylation. 
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Some of these cofactors include members of two families of histone 
acetylases, i. e. CBP/p300 and steroid receptor coactivator (SRC)-1, as well 
as PPAR binding protein (PBP), PPAR gamma coactivator (PGC)-1 and 
silencing mediator for retinoid and thyroid hormone receptors (SMRT).  
CBP and p300 were originally identified as CREB (cAMP-responsive 
binding protein) and E1 A interacting factors (Chrivia et al., 1993; Eckner et 
al., 1994; Janknecht & Hunter, 1996a; Janknecht & Hunter, 1996b). 
CBP/p300 are widely expressed (Misiti et al., 1998) and coactivate numerous 
transcription factors including several nuclear receptors (Chakravarti et al., 
1996; Hanstein et al., 1996; Kamei et al., 1996; Smith et al., 1996; Dowell et 
al., 1997; Kraus & Kadonaga, 1998). CBP/p300 interacts with PPARγ through 
multiple domains in each protein (Gelman et al., 1999). Most notably, the NH2-
terminal region of PPARγ can dimerize with CBP/p300 in the absence of 
ligand and this association enhances its constitutive AF-1 transcriptional 
activity (Gelman et al., 1999). The constitutive presence of CBP/p300 could 
enhance the basal ligand-independent transcriptional activity of PPARγ in vivo 
and could thereby explain the high level of basal activity of PPARγ. 
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1.4 Atherosclerosis  
Atherosclerosis is a complex vascular disease initiated by 
accumulation and oxidation of plasma low-density lipoprotein (LDL) in the 
sub-endothelial space of the vessels. The development of atherosclerosis, 
however, is a complex long term process which involves recruitment and 
activation of different cell types, including monocytes/macrophages, 
endothelial cells, smooth muscle cells and T-lymphocytes in the intima of the 
arteries, thus leading to a local inflammatory response (Ross, 1999).  
The trapped monocytes differentiate into macrophages that take up 
oxidized low-density lipoproteins (OxLDL) through scavenger receptors (SR), 
thus forming foam cells. Activated smooth muscle cells (SMC) proliferate and 
migrate from the media thus leading to neo-intima formation. Activation of 
these cells leads to the release of pro-inflammatory cytokines, which 
combined with the secretion of metalloproteases and expression of pro-
coagulant factors, results in chronic inflammation and plaque instability. This 
can further evolve to plaque rupture and acute occlusion by thrombosis, 
resulting in myocardial infarction and stroke (Figure 1.10) [Ross, 1993; Ross, 
1995; Ross, 1999; Lusis, 2000].  
PPARγ has been reported to play an important role in the development 
of atherosclerosis. Interestingly, there are contradicting reports on the role of 
PPARγ in atherogenesis having demonstrated to produce pro-atherogenic 
effects in some contexts but anti-atherogenic effects in others.    
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Figure 1.10 The atherosclerosis process. (from Lusis, 2000). 
 
 
 
 
 
 
 
 
 
